Literature DB >> 7016335

Disruption of the in vivo distribution of the intermediate filaments in fibroblasts through the microinjection of a specific monoclonal antibody.

J J Lin, J R Feramisco.   

Abstract

Monoclonal antibodies (JLB1 and JLB7) that recognize minor components of the intermediate filament system of cultured cells were introduced into living fibroblasts by microinjection. Several minutes after injection of the JLB7 antibody virtually all of the intermediate filaments of the cells were found to be aggregated into tight bundles near or around the nucleus. In contrast, injection of the JLB1 antibody caused little or no aggregation of the intermediate filaments. Electron microscopy showed that the perinuclear bundles that formed after injection of the JLB7 antibody each consisted of ten or more filaments apparently crosslinked together. Double-label immunofluorescence microscopy showed that virtually all of the vimentin-containing intermediate filaments in the JLB7 antibody-injected cells were redistributed to the perinuclear region and remained there for at least 24 hr. The distributions of actin microfilaments and microtubules were seemingly undisturbed following microinjection. No obvious changes in cell morphology or behavior were apparent in the cells injected with JLB7 antibody; the cells displayed a flat appearance, showed a polarity, were able to ruffle and bleb and even appeared to show the normal saltatory movements of intracellular vesicles, granules and mitochondria, suggesting that intermediate filaments are not involved in these activities. The microinjection of highly specific monoclonal antibodies that recognize and alter components of the cell provides an additional approach to determine the in vivo functions of intracellular elements.

Mesh:

Substances:

Year:  1981        PMID: 7016335     DOI: 10.1016/0092-8674(81)90514-6

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  57 in total

Review 1.  Targeting antibodies to the cytoplasm.

Authors:  Andrea L J Marschall; André Frenzel; Thomas Schirrmann; Manuela Schüngel; Stefan Dübel
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

2.  Onset of human cytomegalovirus replication in fibroblasts requires the presence of an intact vimentin cytoskeleton.

Authors:  Matthew S Miller; Laura Hertel
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

3.  Interaction in vitro of the neurofilament triplet proteins from porcine spinal cord with natural RNA and DNA.

Authors:  P Traub; C E Vorgias; W J Nelson
Journal:  Mol Biol Rep       Date:  1985-04       Impact factor: 2.316

4.  Oxysterol-binding-protein (OSBP)-related protein 4 binds 25-hydroxycholesterol and interacts with vimentin intermediate filaments.

Authors:  Cheng Wang; Lellean JeBailey; Neale D Ridgway
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

5.  Transfer of macromolecules into living adult cardiomyocytes by microinjection.

Authors:  M Bartoli; W C Claycomb
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

Review 6.  The cytoskeletal mechanics of brain morphogenesis. Cell state splitters cause primary neural induction.

Authors:  R Gordon; G W Brodland
Journal:  Cell Biophys       Date:  1987-12

7.  Delivery of antibodies to the cytosol: debunking the myths.

Authors:  Andrea L J Marschall; Congcong Zhang; André Frenzel; Thomas Schirrmann; Michael Hust; Franck Perez; Stefan Dübel
Journal:  MAbs       Date:  2014-05-21       Impact factor: 5.857

8.  Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein.

Authors:  M K Karczewski; K Strebel
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

Review 9.  Microinjection of somatic cells with micropipettes: comparison with other transfer techniques.

Authors:  J E Celis
Journal:  Biochem J       Date:  1984-10-15       Impact factor: 3.857

10.  Giant axonal neuropathy. A neuropathological study.

Authors:  H A Kretzschmar; B O Berg; R L Davis
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.